Ironwood Pharmaceuticals, Inc. today presented efficacy and safety data from two Phase III extension studies of ZURAMPIC , as well as pooled analyses from the two extension studies and from the three pivotal Phase III ZURAMPIC clinical trials, in four poster presentations at the American College of Rheumatology Annual Meeting in Washington, D.C. ZURAMPIC is FDA-approved as a once-daily oral tablet to be taken in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with an XOI alone. ZURAMPIC is not recommended for the treatment of asymptomatic hyperuricemia and should not be used as monotherapy.
Allopurinol, a widely used treatment for lowering serum urate levels, does not appear to increase risk of kidney deterioration in gout patients with normal or near-normal kidney function, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington. Chronic kidney disease is a gradual loss of kidney function that can lead to fluid, electrolyte and waste build-up in its advanced stages.
Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline. Barath Palada, a lead analyst from Technavio, specializing in research on infectious and rare diseases sector, says, " The global gout therapeutics market is expected to witness moderate growth during the forecast period due to the introduction of urate-lowering drugs such as lesinurad and ulodesine for the treatment of gout and increasing prevalence rates.